Inactive Instrument

Highlights Anchiano Therapeutics Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0011267882

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Anchiano Therapeutics : Shareholders OK Pending Chemomab Merger	16/21/16	MT
ChemomAb Ltd. completed the acquisition of Anchiano Therapeutics Ltd. in a reverse merger transaction.	16/21/16	CI
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing	16/21/16	GL
Anchiano Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	10/21/10	CI
ANCHIANO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Anchiano Therapeutics Ltd. - ANCN	16/21/16	BU
Anchiano Therapeutics : Chemomab Plan Merger to Advance Treatment for Fibrosis-Related Diseases	15/20/15	MT
Anchiano Therapeutics : and Chemomab Announce Entry Into Definitive Merger Agreement	15/20/15	AQ
ChemomAb Ltd. entered into letter of intent to acquire Anchiano Therapeutics Ltd. for for $27.2 million in a reverse merger transaction.	15/20/15	CI
Anchiano Therapeutics Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	16/20/16	CI
Anchiano Therapeutics Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2020	14/20/14	CI
Anchiano Therapeutics Ltd Reports Earnings Results for the First Quarter Ended March 31, 2020	08/20/08	CI
Anchiano Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2019	18/20/18	CI
Anchiano Therapeutics Ltd Reports Earnings Results for the Third Quarter Ended September 30, 2019	15/19/15	CI
Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer; Company Focuses on Advancing Pan-RAS Inhibitor Program	15/19/15	CI
Anchiano Therapeutics Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019	06/19/06	CI
Anchiano Therapeutics Ltd. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2019	22/19/22	CI
Anchiano Therapeutics Ltd. Reports Consolidated Earnings Results for Fourth Quarter and Full Year Ended December 31, 2018	13/19/13	CI
Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering	15/19/15	GL
Anchiano Therapeutics Announces Initiation of its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer	18/18/18	CI
Anchiano Therapeutics Ltd Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	19/18/19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Anchiano Therapeutics Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0011267882

Highlights

Filters